| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Atherosclerosis and Lipoproteins |
From the Department of Epidemiology & Biostatistics (A.E.H., H.A.P.P., A.H., J.C.M.W.) and the Department of Internal Medicine (A.E.H., H.A.P.P.), Erasmus University Medical School, Rotterdam, the Netherlands, and the Department of Clinical Epidemiology (A.M.v.H.), Leiden University Medical Centre, Leiden, the Netherlands.
Correspondence to Dr J.C.M. Witteman, Department of Epidemiology & Biostatistics, Erasmus University Medical School, PO Box 1738, 3000 DR Rotterdam, The Netherlands. E-mail witteman{at}epib.fgg.eur.nl
| Abstract |
|---|
|
|
|---|
Key Words: atherosclerosis vascular calcification osteoporosis menopause
| Introduction |
|---|
|
|
|---|
Several cross-sectional studies have been conducted on the association between atherosclerotic calcification and osteoporosis among elderly women.3 4 5 6 7 8 21 22 23 Most of these studies found an association,3 4 5 6 7 8 although some did not.21 22 23 Potential confounding factors other than age have not been taken into account in most of these studies.3 4 5 8 21 22 No study examined whether progression of atherosclerotic calcification is associated with bone loss. Because the prevalence of atherosclerosis and osteoporosis increases from menopause onward,24 25 the change from the premenopausal to the postmenopausal state may be an appropriate period to study this association longitudinally.
In the present population-based study, we examined the association between progression of aortic calcification and metacarpal bone loss during menopause in 236 women. In addition, we studied the cross-sectional association between the extent of aortic calcification and metacarpal bone mass and density in 720 postmenopausal women.
| Methods |
|---|
|
|
|---|
Measurement of Aortic Calcification
Aortic calcification was diagnosed by radiographic
detection of calcified deposits in the abdominal aorta.26
At baseline and at follow-up, lateral abdominal films (T12-S1) were
made from a fixed distance while the subject was seated. Aortic
calcifications were considered present when linear densities were
seen in an area parallel and anterior to the lumbar spine (L1-L4).
Baseline and follow-up values for the extent of calcification were
scored according to the length of the involved area (
1 cm, 2 to 5 cm,
6 to 10 cm, and >10 cm). In the analyses, we considered the
first 2 classes as mild calcification and the third and fourth classes
as advanced calcification.
Progression of calcification was defined as the occurrence of new calcifications or enlargement of the calcified area present at baseline. Baseline and follow-up films were examined in pairs. The extent of progression was graded, but because of the relatively small numbers in the categories, we combined severity grades into 2 groups: progression absent and progression present. No subject showed a decrease in the extent of aortic calcification.
All films were examined by 2 independent observers without knowledge of
the metacarpal bone mass and density of the subjects. Before the
scoring, a sample of the films was read by the 2 observers
simultaneously so as to reach agreement on interpretation
of the scoring protocol. Observers were aware of the date of the
radiographs. If there were differences between observers regarding
readings, films were reviewed by both observers
simultaneously so as to reach consensus. The score that was
agreed upon by both observers was recorded. The percentage of
agreement for absence versus presence of progression was 88%, and the
statistic was 0.74.
The validity of radiographic assessment of aortic intimal calcification was studied by comparisons made on necropsy material. The method was shown to be highly specific, and in most cases, visible calcification represented advanced atherosclerosis.27 A comparison study with computed tomography in 56 unselected elderly subjects showed that calcifications that were detected on the abdominal x-ray in 32 subjects were independently shown to be located in the aorta on the corresponding CT images in all but 1 subject.26 Moreover, aortic calcification is known to be associated with cardiovascular disease risk factors26 28 and atherosclerosis at other sites29 and to predict cardiovascular morbidity and mortality.18 19 Comparison of roentgenographic aortic calcification with coronary artery calcium as detected by electron beam tomography within 457 subjects showed that aortic calcification was present in 3.9%, 13.7%, and 31.5% of the subjects within the lowest, the middle, and the highest tertile of coronary artery calcium, respectively (P for trend<0.001, adjusted for age and sex). These results indicate that aortic calcification is strongly related to coronary calcification.
Metacarpal Radiogrammetry
Anteroposterior radiographs of the hands were used for
measurements of the cortical thickness of metacarpals II, III, and IV
of both hands. At baseline and at follow-up, measurements of the outer
diameter (D) and the medullar diameter (d) of the metacarpal bones were
conducted at the midshaft with the use of a x7 magnifying loupe with
an accuracy of 0.01 mm. The metacarpal cortical area (MCA) was
calculated as the mean value of
D2-d2 for 6 metacarpals.
As a standardization for differences in body size, the relative
cortical area (RCA) was calculated. This was achieved by expressing the
MCA as a percentage of the size of the metacarpal bone:
100%x(D2-d2)/D2
for each metacarpal bone.30 31 The mean value of the 6
metacarpals was used for the analyses. The MCA and RCA can be
interpreted as indicators of bone mass and bone density, respectively.
For the MCA and the RCA, the total loss during follow-up was calculated
by subtracting the baseline measurements from those at follow-up. The
observers measuring the metacarpal bone mass and density were unaware
of the aortic calcification score of the subjects.
We estimated the measurement precision of metacarpal radiogram-metry in 100 duplicate measurements. The mean intraindividual standard deviation of a duplicate measurement was 1.9 mm2 (4% of the initial mean value) for MCA and 2.5 mm2 % (3% of the initial mean value) for RCA, which is sufficient to allow inferences concerning bone loss after a 9-year period. In women, the mineral content of the metacarpals correlates well with that at other peripheral skeletal bone sites (r ranges from 0.75 to 0.96).32 The accuracy of the measurement was demonstrated by Exton-Smith et al,33 who found a correlation of 0.85 between the mineral content of the metacarpal cortical area and the ash mineral content of the metacarpal bones.
Menopausal State
Menopausal state was assessed by a self-administered
questionnaire that asked whether the menses had stopped and, if so, at
what age and the reason for their cessation (natural or artificial).
The type of artificial menopause was ascertained during an interview by
a doctor. Postmenopausal state was defined as no menstruation for at
least 1 year.
Assessment of Covariates
Assessment of covariates was similar at baseline and at
follow-up. Height and weight were measured without shoes and with
indoor clothing. Body mass index was calculated
(weight/height2). Blood pressure was measured
with a random zero sphygmomanometer with the subject seated. The mean
of 2 readings was reported. Serum total cholesterol at
baseline was measured by an automatic enzymatic method. During
follow-up, a modified reagent was used (CHOD/PAP High
Performance, Boehringer-Mannheim). Information on
smoking habits and medical history was obtained by a self-administered
questionnaire, which was checked during an interview by the study
physician. Diabetes mellitus was considered present when it was
reported in the questionnaire and confirmed during the interview with
the physician. Subjects were asked to bring their current medication to
the research center, where treatments were noted.
Population for Analyses
Of the 855 women examined at follow-up, menstruation had ceased
for <1 year in 7 women, and for 11 women, information on menopausal
state was missing. Because films were missing or not readable,
information on aortic calcification and/or metacarpal bone density was
missing in 45 women, leaving 792 postmenopausal women. Of these women,
282 were premenopausal at baseline. Data on progression of aortic
calcification or bone loss were missing in 27 women. Age at menopause
could not be ascertained for 19 women, leaving 236 women for the
analyses of the association between progression of aortic
calcification and bone loss. The mean duration of follow-up for these
women was 8.9±0.8 years. For the cross-sectional analyses in
postmenopausal women at follow-up, we excluded women with missing
information on age at menopause only if their age at follow-up was <60
years (n=72), because we assumed elderly women to be postmenopausal.
This left 720 postmenopausal women for the cross-sectional
analyses at follow-up.
Data Analysis
Initially, we compared continuous baseline characteristics
between premenopausal women with and without progression of aortic
calcification during follow-up by use of a general linear model,
adjusted for age. Dichotomous variables were compared by a
2 test.
We used a general linear model to compute and compare adjusted mean values of metacarpal bone loss in categories of progression of aortic calcification. The cross-sectional association between aortic calcification and metacarpal bone mass and density in all postmenopausal women at follow-up was assessed by linear regression analysis with MCA and RCA as dependent variables and the variable indicating the extent of aortic calcification (no, mild, or advanced) as an independent variable. A test of significance for the coefficient of this ordinal variable was considered to be a test for trend. Adjusted mean values of bone mass and density in categories of aortic calcification were computed by use of a general linear model.
Statistical significance was considered to be present at P<0.05. SPSS 8.0 for Windows was used for analyses.
| Results |
|---|
|
|
|---|
|
During follow-up, progression of aortic calcification was observed in 59 women going through menopause (25%). No subject showed a decrease in the extent of aortic calcification. Compared with premenopausal women without progression of aortic calcification during follow-up, women with progression of aortic calcification had a higher systolic blood pressure (136 versus 130 mm Hg, respectively; P=0.03), a higher serum cholesterol (6.2 versus 5.7 mmol/L, respectively; P<0.001), both adjusted for age, and smoked more (56% versus 31%, respectively; P=0.001) at baseline. No significant differences were seen in other cardiovascular disease risk factors.
Among women with progression of aortic calcification, the average loss
of initial metacarpal bone mass was 6.1%; their average loss of
initial metacarpal bone density was 8.9%. In women without progression
of aortic calcification, these losses were 3.9% and 6.9%,
respectively. Additional adjustment for potential confounding factors
did not influence these results (Table 2
), nor did additional adjustment for
cardiovascular disease history (data not shown). In
women already postmenopausal at baseline, there was no association
between progression of aortic calcification and metacarpal bone loss
during follow-up (data not shown).
|
We detected an inverse, graded, cross-sectional association between
extent of aortic calcification and metacarpal bone mass and density in
all postmenopausal women at follow-up, adjusted for age (Table 3
). Again, additional adjustment for
potential confounders did not influence the results (Table 3
),
nor did additional adjustment for cardiovascular
disease history (data not shown).
|
| Discussion |
|---|
|
|
|---|
When interpreting our results, some methodological issues should be taken into account. An advantage of the present study is the fact that the association between progression of aortic calcification and bone loss was studied during menopause, the period from which the prevalence of atherosclerosis and osteoporosis increases.24 25 The prevalence of hormone replacement therapy use in our population was low, which was common in the Netherlands during the period the present study was conducted.34 We measured aortic calcification radiographically. We assume that this is intimal calcification, which is clearly distinguishable from medial calcification.35 A limitation of our measurement of aortic calcification is the fact that it detected progression in a linear manner, whereas in fact it may have been circumferential. However, we assume that errors in the measurement of progression of aortic calcification and bone loss occurred randomly, which means that, if anything, we underestimated the association between progression of aortic calcification and bone loss. Although the density of calcification may be relevant with respect to plaque vulnerability and the subsequent onset of acute coronary events, the present study does not provide data on the density of calcification. No woman showed a decrease in the extent of aortic calcification. However, the fact that readers were aware of dates of the radiographs could have biased them against the detection of decreased calcification. Lack of information contributed to loss of data. We assume that the association between progression of aortic calcification and metacarpal bone loss will not differ between subjects with or without complete availability of data, making selection bias unlikely.
We are the first to describe an association between progression of atherosclerotic calcification and bone loss in women during menopause. The results of the present study are in line with those previous studies that showed a cross-sectional association between bone mineral density and aortic calcification,3 4 5 6 carotid plaques,7 and coronary calcification8 among elderly women. Most of the reported studies, however, did not adjust for potential confounding factors apart from age.3 4 5 8 21 22 Vogt et al23 found an association between aortic calcification and bone mineral density at 2 of the 5 measured sites, which remained after adjustment for potential confounders. Two studies in elderly women found an adjusted association between bone mass and density at baseline and cardiovascular death9 and mortality due to stroke10 during follow-up.
Atherosclerotic calcification and bone mineralization show similarities. The mineral within calcified atherosclerotic plaques is hydroxyapatite, the same mineral found in bone,11 and matrix vesicles, the initial nucleation sites for hydroxyapatite mineral in bone, are found in atherosclerotic lesions.12 Calcifying vascular cells appear in many ways similar to osteoblasts,13 and specific factors and proteins crucial to bone formation are also present within atherosclerotic lesions. The bone differentiation factor bone morphogenetic protein-2a has been found in atherosclerotic lesions,14 and arterial calcification involves a variety of bone matrix proteins, such as type-I collagen,15 and the noncollagenous proteins osteopontin11 and osteocalcin.16
The association between progression of aortic calcification and bone loss during menopause may result from a common etiologic factor, such as estrogen deficiency. Epidemiological data suggest that estrogen deficiency is a risk factor for cardiovascular disease and osteoporosis.36 37 Arteries and bone are target organs for estrogen. Estrogen receptors have been demonstrated on vascular endothelial and smooth muscle cells,38 osteoblasts,39 and osteoclasts,40 suggesting a direct effect of estrogen on vascular and bone cells. Whereas all subjects went through menopause, women with progression of aortic calcification had more bone loss than women without progression of aortic calcification, suggesting that there could be a difference in estrogen loss between subjects. On the other hand, it may not be estrogen deficiency per se, but sensitivity to estrogen deficiency (eg, due to variability of the estrogen receptor gene)41 that is the common etiologic factor.
Calcium-regulating hormones may be involved in the association between vascular calcification and osteoporosis. Parathyroid hormone levels increase with aging.42 Concurrently, estrogen deficiency is suggested to increase the sensitivity of the skeleton to parathyroid hormone43 and to reduce intestinal calcium absorption.44 Hyperparathyroidism, which can also be induced in the elderly by vitamin D deficiency, can on the one hand contribute to bone loss45 and on the other hand add to soft tissue calcium deposition, in particular, vascular calcification.
Alternatively, it may not be calcification itself but progression of the underlying process of atherosclerosis that is associated with bone loss. Estrogen deficiency may have indirect effects on arteries and bone by the production of inflammatory agents, such as interleukin-1 and -6 and tumor necrosis factor,46 which are involved in atherogenesis47 and contribute to bone resorption.48 49 50 Another common factor to explain the apparent association between atherosclerosis and bone loss may be the presence of oxidized lipids, which promote atherogenesis51 and inhibit differentiation and mineralization of bone cells.52 Plasma homocysteine is a cardiovascular risk factor that increases after menopause,53 and osteoporosis is a common feature in patients with homocystinuria.54 Although no association between homocysteine and bone density was found in a small group of postmenopausal women,55 hyperhomocysteinemia might be involved in the association between atherosclerosis and osteoporosis.
In summary, our results indicate that progression of atherosclerotic calcification is associated with bone loss in women during menopause, suggesting a common etiologic factor.
| Acknowledgments |
|---|
Received October 5, 1999; accepted March 21, 2000.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
G. M. London, S. J. Marchais, A. P. Guerin, P. Boutouyrie, F. Metivier, and M.-C. de Vernejoul Association of Bone Activity, Calcium Load, Aortic Stiffness, and Calcifications in ESRD J. Am. Soc. Nephrol., September 1, 2008; 19(9): 1827 - 1835. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. L. Demer and Y. Tintut Vascular Calcification: Pathobiology of a Multifaceted Disease Circulation, June 3, 2008; 117(22): 2938 - 2948. [Full Text] [PDF] |
||||
![]() |
L. N. Bakhireva, G. A. Laughlin, R. Bettencourt, and E. Barrett-Connor Does Osteoprotegerin or Receptor Activator of Nuclear Factor-{kappa}B Ligand Mediate the Association between Bone and Coronary Artery Calcification? J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 2009 - 2012. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Raggi and M. Kleerekoper Contribution of Bone and Mineral Abnormalities to Cardiovascular Disease in Patients with Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., May 1, 2008; 3(3): 836 - 843. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Cozzolino and D. Brancaccio Is PTH a risk factor for cardiovascular calcifications in haemodialysis? Nephrol. Dial. Transplant., March 1, 2008; 23(3): 1067 - 1068. [Full Text] [PDF] |
||||
![]() |
G. Coen Reply Nephrol. Dial. Transplant., March 1, 2008; 23(3): 1068 - 1069. [Full Text] [PDF] |
||||
![]() |
Y. Orita, H. Yamamoto, N. Kohno, M. Sugihara, H. Honda, S. Kawamata, S. Mito, N. N. Soe, and M. Yoshizumi Role of Osteoprotegerin in Arterial Calcification: Development of New Animal Model Arterioscler. Thromb. Vasc. Biol., September 1, 2007; 27(9): 2058 - 2064. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Marz, U. Seelhorst, B. Wellnitz, B. Tiran, B. Obermayer-Pietsch, W. Renner, B. O. Boehm, E. Ritz, and M. M. Hoffmann Alanine to Serine Polymorphism at Position 986 of the Calcium-Sensing Receptor Associated with Coronary Heart Disease, Myocardial Infarction, All-Cause, and Cardiovascular Mortality J. Clin. Endocrinol. Metab., June 1, 2007; 92(6): 2363 - 2369. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Galassi, D. M. Spiegel, A. Bellasi, G. A. Block, and P. Raggi Accelerated vascular calcification and relative hypoparathyroidism in incident haemodialysis diabetic patients receiving calcium binders Nephrol. Dial. Transplant., November 1, 2006; 21(11): 3215 - 3222. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Westenfeld, M. Ketteler, and V. M. Brandenburg Anti-RANKL therapy--implications for the bone-vascular-axis in CKD? Denosumab in post-menopausal women with low bone mineral density Nephrol. Dial. Transplant., August 1, 2006; 21(8): 2075 - 2077. [Full Text] [PDF] |
||||
![]() |
A. H. E. M. Maas, Y. T. van der Schouw, D. Beijerinck, J. J. M. Deurenberg, W. P. T. M. Mali, and Y. van der Graaf Arterial Calcifications Seen on Mammograms: Cardiovascular Risk Factors, Pregnancy, and Lactation Radiology, July 1, 2006; 240(1): 33 - 38. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wang, W. Zhang, Y. Zhang, Y. Yang, L. Sun, S. Hu, J. Chen, C. Zhang, Y. Zheng, Y. Zhen, et al. VKORC1 Haplotypes Are Associated With Arterial Vascular Diseases (Stroke, Coronary Heart Disease, and Aortic Dissection) Circulation, March 28, 2006; 113(12): 1615 - 1621. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Pinheiro, C. M. Castro, and V. L. Szejnfeld Low femoral bone mineral density and quantitative ultrasound are risk factors for new osteoporotic fracture and total and cardiovascular mortality: a 5-year population-based study of brazilian elderly women. J. Gerontol. A Biol. Sci. Med. Sci., February 1, 2006; 61(2): 196 - 203. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Bezerra, G. D. Calomeni, V. F. Caparbo, E. S. Gebrim, M. S. Rocha, and R. M. R. Pereira Low bone density and low serum levels of soluble RANK ligand are associated with severe arterial calcification in patients with Takayasu arteritis Rheumatology, December 1, 2005; 44(12): 1503 - 1506. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Adams and J. Pepping Vitamin K in the treatment and prevention of osteoporosis and arterial calcification Am. J. Health Syst. Pharm., August 1, 2005; 62(15): 1574 - 1581. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Hamerman Osteoporosis and atherosclerosis: biological linkages and the emergence of dual-purpose therapies QJM, July 1, 2005; 98(7): 467 - 484. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Karasik, S. Demissie, L. A. Cupples, and D. P. Kiel Disentangling the Genetic Determinants of Human Aging: Biological Age as an Alternative to the Use of Survival Measures J. Gerontol. A Biol. Sci. Med. Sci., May 1, 2005; 60(5): 574 - 587. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Somjen, Y. Weisman, F. Kohen, B. Gayer, R. Limor, O. Sharon, N. Jaccard, E. Knoll, and N. Stern 25-Hydroxyvitamin D3-1{alpha}-Hydroxylase Is Expressed in Human Vascular Smooth Muscle Cells and Is Upregulated by Parathyroid Hormone and Estrogenic Compounds Circulation, April 5, 2005; 111(13): 1666 - 1671. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Collin-Osdoby Regulation of Vascular Calcification by Osteoclast Regulatory Factors RANKL and Osteoprotegerin Circ. Res., November 26, 2004; 95(11): 1046 - 1057. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Jorgensen, O. Joakimsen, G. K. Rosvold Berntsen, I. Heuch, and B. K. Jacobsen Low Bone Mineral Density Is Related to Echogenic Carotid Artery Plaques: A Population-based Study Am. J. Epidemiol., September 15, 2004; 160(6): 549 - 556. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Rubin and S. J. Silverberg Vascular Calcification and Osteoporosis--The Nature of the Nexus J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4243 - 4245. [Full Text] [PDF] |
||||
![]() |
E. Schulz, K. Arfai, X. Liu, J. Sayre, and V. Gilsanz Aortic Calcification and the Risk of Osteoporosis and Fractures J. Clin. Endocrinol. Metab., September 1 |